70 results about "Low dose" patented technology

The invention relates to a double-cavity radiotherapy and chemotherapy integrated treatment capsule for brain glioma, which aims to solve the problems that the existing radioactive seed source or chemotherapy carrier cannot give consideration to radiotherapy and chemotherapy, the dosage is difficult to regulate and control, the medicine distribution is non-uniform and the like. The brain glioma double-cavity radiotherapy and chemotherapy integrated treatment bag is composed of a radiotherapy pipeline and a chemotherapy pipeline, the whole integrated treatment bag is a spiral pipe body, the radiotherapy pipeline is located in an inner ring, the chemotherapy pipeline is located in an outer ring, the radiotherapy pipeline is a closed cavity, a liquid radioactive source is contained in the closed cavity, and the liquid radioactive source is located in an outer ring. The chemotherapy medicine is released from the head end of the chemotherapy pipeline, the chemotherapy medicine is injected from the tail end of the chemotherapy pipeline, and the surface of the integrated treatment bag is coated with a composite antibacterial layer. According to the integrated treatment capsule, radiopharmaceuticals and chemical drugs are placed in the inner cavity and the outer cavity respectively, synergistic treatment of radiotherapy and chemotherapy is achieved through the synchronous effect of the two channels, and long-term low-dose release of the radiopharmaceuticals and the chemotherapy drugs is achieved and toxic and side effects are reduced by adjusting the screw pitch and the thickness of the tube wall.

The invention provides a low-dose CT image processing method and device, electronic equipment and a medium, and relates to the field of medical image processing, and the method comprises the steps: obtaining a to-be-processed low-dose CT image; performing noise characteristic quantization on the low-dose CT image to generate noise characteristics; extracting image features of the low-dose CT image by adopting a trained image processing model, fusing the image features with the noise features to obtain fused features, and processing the fused features to obtain a target CT image; according to the method, accurate denoising of the low-dose CT image can be realized, diagnosis details such as organ boundaries and blood vessels are efficiently reserved, the robustness of the model to various noise scenes is enhanced, the calculation overhead is reduced, and a high-quality target CT image meeting clinical diagnosis requirements is output.

This invention discloses a method for detecting the toxicity threshold of a substance based on a rat drinking experiment. The method of this invention includes the following steps: First, a drinking preference experiment is conducted, and then the toxicity threshold is determined: the amount of substance water and pure water consumed in the drinking preference is compared to determine the time when the rat begins to significantly avoid substance water, the mass of the toxic substance in the rat's body at that time is calculated, and the toxicity threshold of the rat is calculated; (3) dose conversion from rat to human: based on the interspecies dose conversion of body surface area, the toxicity threshold of the rat is first converted into the equivalent dose for humans to obtain the acute exposure dose, and then the acute exposure dose is converted into the chronic exposure dose for humans to obtain the substance toxicity threshold. This invention can accurately determine the toxicity threshold: it achieves toxicity assessment of low-dose exposure through spontaneous recognition behavior; it is easy to operate; and it is applicable to the toxicity assessment and non-destructive threshold determination of various substances such as environmental pollutants, chemical substances, and drugs.

The present disclosure provides an IL-6 formulation, comprising about 40 μg / mL to about 2 mg / ml IL-6, about 5 to about 15 mM histidine, about 5 to about 15 mg / mL glycine, about 40 to about 60 mg / mL trehalose, about 0.1 to about 0.3 mg / mL polysorbate 20, and about 1 to about 1000 μM DTPA, wherein the formulation has a pH of about 6.0 to about 8.0. Such formulations may be useful to treat and / or prevent a disease or disorder in a subject in need thereof.

Embodiments provide targeted delivery of powder medications (high and low dose) within the nose and to different nasal regions. Oscillating jet technology provides a unique approach to minimize hotspot formation and the associated irritation associated with high powder mass applications together with improved posterior surface area coverage and improved drug absorption for locally acting or systemically and neurologically targeted medications.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

The invention belongs to the field of X-ray long-afterglow luminescent materials. The technical problems that traditional Pr < 3 + > doped fluoride is insufficient in afterglow performance, X-ray imaging depends on continuous irradiation, and color scattering noisy points exist are solved. The NaLuF4: Mg / Cs / Pr fluoride material is prepared by adopting a Cs < + >-Mg < 2 + > co-doping regulation strategy, the material is synthesized by an oleic acid-octadecene liquid phase method, and the X-ray excitation afterglow intensity of Pr < 3 + > is improved by about 110 times by utilizing the synergistic effect that Cs < + > enhances X-ray absorption and Mg < 2 + > optimizes a carrier shallow-deep trap level; the material is prepared into the high-light-transmittance rare earth nano flexible scintillation screen with the resolution ratio of 20.01 lp / mm. According to the invention, zero-noisy-point time-delay imaging after low-dose X-ray transient irradiation is realized, continuous irradiation is not needed, the radiation dose is lower, and the method is mainly applied to the field of X-ray time-delay imaging of low-dose medical diagnosis and industrial nondestructive testing. The method does not need continuous X-ray irradiation, and has important application value in the fields of medical diagnosis, industrial nondestructive testing and the like.

The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg / kg / dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

The invention discloses a low-dose CT denoising method and device based on wavelet transform and a state space model, and relates to the technical field of medical image processing. The method comprises the following steps: acquiring a low-dose CT image and a corresponding full-dose CT image, and generating a data set; dividing the data set into a training set and a test set according to a preset proportion; constructing and training a CT denoising network, taking the training set as an input parameter, taking the predicted image as an output parameter, and taking the minimum error absolute value of the full-dose CT image and the predicted image as a loss function; and inputting the test set into the trained CT denoising network in the step S3 to obtain a prediction image. According to the low-dose CT denoising method, global dependence can be efficiently established, and details can be accurately reserved.

This invention discloses an intelligent adaptive dose verification calculation method and system. The intelligent adaptive dose verification calculation method includes: obtaining preliminary dose distribution data for a patient based on a deep learning-based dose prediction model; dynamically assigning variance reduction parameters to particles in a Monte Carlo simulation based on the high and low dose distribution information in the preliminary dose distribution data, wherein the variance reduction parameters include simulation weights, with simulation weights assigned to particles predicted to be in high-dose regions being less than those assigned to particles predicted to be in low-dose regions; and using a Monte Carlo dose calculation engine, simulating the planned beam based on the dynamically assigned variance reduction parameters to obtain high-precision verification dose distribution data. This invention's intelligent adaptive dose verification calculation method ensures the physical authenticity of the final verification dose distribution and the credibility of the "gold standard."

The application discloses application of a low-dose anti-PD-1 antibody in a limited course of treatment in treatment of hepatitis B. Anti-PD-1 antibody treatment is carried out on a chronic hepatitis B patient receiving nucleoside analogue or nucleotide analogue treatment, 100 mg is injected intravenously each time, once every three weeks, and the course of treatment is ended after 12 weeks or 24 weeks. The application blocks the combination of the PD-1 receptor highly expressed on the surface of T cells of the CHB patient with a ligand by blocking the CHB patient T cell surface high expression of the PD-1 receptor, thereby reversing the T cell exhaustion state, enhancing the HBV specific T cell immune response, and promoting HBsAg clearance. The application uses a limited course of treatment and a low-dose alpha PD-1 to enhance the HBV specific T cell immune response of the patient and promote the clearance of HBsAg while ensuring good safety. Compared with the traditional 48-week Peg-IFN alpha or several years or even decades of NAs treatment of the CHB patient, the 12-week or 24-week course of alpha PD-1 is shorter and has a smaller economic burden on the patient.

Provided herein is a method of adoptive cell therapy. The method includes administering to a subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes. Also provided herein is a method of treating cancer in a subject by administering to the subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes.

The application relates to the technical field of scintillator screen and discloses a flexible scintillator screen with low-dose X-ray imaging performance and a process thereof, which comprises a high-efficiency 2D perovskite scintillator material layer, a transparent conductive polymer layer and a flexible substrate, the high-efficiency 2D perovskite scintillator material is Cs2AgBiBr6, the flexible substrate is a polyimide film or a PET film, the transparent conductive polymer layer is arranged on one side or both sides of the high-efficiency 2D perovskite scintillator material layer, and the transparent conductive polymer layer material is PEDOT:PSS or PANI. The low-dose X-ray imaging performance is improved through the micro-nano structure and the gradient structure; the micro-nano structure can control the propagation and emission direction of the scintillator light emission, improve the light extraction efficiency or the detection sensitivity; the gradient structure matches the intensity difference of the X-ray penetrating object, avoids signal saturation or loss, and optimizes the light collection efficiency and the imaging quality.

This document provides an apparatus for delivering solid and gaseous carbon dioxide, comprising: (i) a liquid carbon dioxide source including a tank containing liquid carbon dioxide; (ii) a first conduit including a proximal end operatively connected to the liquid carbon dioxide source and a distal end operatively connected to an orifice; (iii) a second conduit operatively connected to the orifice to guide a mixture of gaseous and solid carbon dioxide to a desired destination; and (iv) a third conduit operatively connected to the second conduit, wherein the third conduit includes a portion configured to sufficiently slow the flow of solid carbon dioxide through that portion of the third conduit to cause the solid carbon dioxide to agglomerate before exiting the third conduit through an opening. The apparatus is capable of delivering a precise dose of carbon dioxide at a desired solid-to-gas ratio under low-dose conditions and / or intermittent conditions.

The application relates to a method for constructing an experimental autoimmune prostatitis rat model, which comprises the following steps: S1, preparing a prostate specific antigen mixture; S2, selecting male SD rats as experimental rats and dividing the rats into a physiological saline control group, a low-dose model group and a high-dose model group; S3, continuously injecting for 7 days, wherein the physiological saline control group receives 0.2ml of physiological saline injection every day, the low-dose model group receives 0.1ml of the prostate specific antigen mixture injection every day, and the high-dose model group receives 0.2ml of the prostate specific antigen mixture injection every day; and S4, continuing to feed all the experimental rats in the groups until the 28th day, wherein the experimental rats in the low-dose model group and the high-dose model group are induced by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and an experimental autoimmune prostatitis rat model is obtained. The method can not only reduce the use of animals and the cost, but also improve the modeling efficiency and stability.

Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent.

The invention discloses a product irradiation monitoring system and method, and relates to the field of product monitoring. The system comprises an irradiation source device, a product conveying device and an environment monitoring unit, and real-time correction is carried out by constructing a voxelization three-dimensional dose rate grid and combining source activity decay and air density parameters; a path integration algorithm is used to calculate a dynamic accumulated dose according to the instantaneous position and speed of the product, and the transmission frequency is adjusted in a closed-loop manner. The system is also integrated with a non-contact dose verification unit based on passive RFID for model calibration, and an excessive radiation estimation and automatic source reduction protection mechanism for a card chain fault. According to the invention, through multi-dimensional environment perception and dynamic integral calculation, the problems of low dose control precision and lack of real-time feedback in traditional irradiation processing are effectively solved, and the stability and safety of product irradiation quality are ensured.

The utility model relates to the technical field of medical instruments, in particular to a blister box which comprises a box body, and a main clamping groove used for loading a main product, an auxiliary clamping groove used for loading an auxiliary product of the main product, an auxiliary clamping groove used for loading a drying agent and an oxygen absorbent and an airflow groove used for air circulation in the box body are formed in the box body. The main clamping groove, the auxiliary clamping groove and the auxiliary clamping groove are communicated through the airflow grooves to form a coherent airflow channel, and the airflow channel is provided with an air inlet and an air outlet which penetrate through the box body. Integrated combined packaging and sterilization of a main product and an auxiliary product can be achieved, low-dose irradiation sterilization is met, the main clamping groove, the auxiliary clamping groove and the auxiliary clamping groove are communicated with one another through the airflow groove formed in the box body to form a coherent airflow channel, gas in the box body can be effectively replaced, water and oxygen retention in the box body is avoided, and the packaging effect is good. The influence of water oxygen on the service life of a main product is reduced.

Medical devices capable of filling liquid into a syringe barrel while evacuating any air from the syringe are described. An exemplary medical device includes a syringe barrel having a tapered sidewall portion for permitting air to vent from the chamber and preventing liquid from exiting the chamber, a plunger rod, and stopper. Another exemplary medical device includes a syringe barrel having a plurality of air venting grooves associated with the sidewall of the barrel, a plunger rod and stopper. Also described is a medical device including a syringe barrel, plunger rod and stopper having a porous plug. Described is a medical device including a syringe barrel having a plurality of air venting grooves associated with the sidewall of the barrel and a porous membrane disposed over the air venting grooves, a plunger rod and stopper. Methods for filling a syringe barrel with a liquid are also provided.

Provided herein is a method of adoptive cell therapy. The method includes administering to a subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes. Also provided herein is a method of treating cancer in a subject by administering to the subject a low dose lymphodepletion regimen and administering to the subject a population of tumor infiltrating lymphocytes.

The present invention provides a computer-implemented method for determining a treatment plan for a radiotherapy treatment including a dose distribution, the method comprising the steps of determining a transition region target thickness of a transition region comprised in a low dose target volume and adjacent to a high dose target volume. The method further comprises creating shells and determining, for each of the shells, a shell-specific upper dose constraint. The method further comprises generating, by means of an optimization algorithm, a treatment plan, the optimization algorithm constrained by a predetermined lower dose constraint in the high dose target volume, an upper dose constraint in the low dose target volume, and the respective shell-specific upper dose constraint.

The invention relates to a breast tomography apparatus with a self-shielding and movable gantry. According to the breast tomography device, X-rays with extremely low dose can be emitted, and free installation and movement can be achieved through self-shielding of the X-rays. Especially, under the condition that breasts are not pressed, examination without physical and clinical limitation can be achieved through a complete three-dimensional image; various clinical conditions can be examined comfortably and accurately with minimal face-to-face contact without additional examinations such as MRI or ultrasound. The shot image can provide substantive change information, and the utilization rate of the image can be improved to the maximum extent by combining artificial intelligence (AI).

The present application relates to the technical field of radiotherapy control, and discloses a treatment control method and system for AB-BNCT. The method comprises the following steps: sending a beam-out condition verification request and a beam-out safety verification request in response to a beam-out request; sending a beam-out button display instruction after receiving the pass results, so that the beam-out button is displayed based on a preset state; monitoring main real-time beam data in real time in response to a state change of the beam-out button; determining a main real-time neutron absorption dose based on the main real-time beam data; and sending a beam control instruction to an accelerator based on the main real-time neutron absorption dose and a target neutron absorption dose, so that the accelerator controls the beam in response to the beam control instruction. By comparing the real-time dose with the target dose, the treatment is continued or stopped, and the accuracy of the treatment and the safety of the patient are ensured. The present application solves the technical problems of low safety and dose verification lag in the existing AB-BNCT treatment, and improves the safety and efficiency of AB-BNCT treatment.

The invention discloses an orthopedic surgery low-dose three-dimensional scanning and navigation method based on robot pose optimization, and relates to the technical field of medical robots and computer-aided surgical operations. Comprising a scanning data acquisition module, an image reconstruction module, a demonstration data acquisition module, a pose optimization module, a simulation learning module, a navigation planning module and a motion control module. The scanning data acquisition module is used for scanning the bone tissue of a patient through low-dose three-dimensional scanning equipment to obtain sparse projection data, pose calculation, path planning and force control are integrated into a whole, a set of complete autonomous solution is formed, excessive dependence on personal experience and operation of an operator is reduced, and the accuracy of the system is improved. The learning curve is shortened, and the operation standardization degree and the overall success rate can be improved.

The present invention provides an injectable depot composition comprising linagliptin and low-dose liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc. In addition, compared to the conventional liraglutide dosage form of once-daily subcutaneous injection, the depot composition of linagliptin and liraglutide of the present invention can significantly improve patient convenience and patient compliance by unifying the administration route and improving the administration cycle.

The application discloses a kind of low-dose CT reconstruction methods of prior image and convolution sparse network in combination, belong to computer tomography technical field.The present application includes the following steps: first, using distinctive feature representation method obtains high-quality prior image;Second, design the convolution sparse network of feature fusion;Next, the error of reconstruction image and prior image is calculated, and iterative reconstruction gradient is estimated according to error;Then, the reconstructed image is fine-tuned using total variation constraint;Finally, the iterative reconstruction of low-dose CT is realized by module cascade form.The present application algorithm comprehensively utilizes the advantage of prior image of plan scanning and convolution sparse network, has explainable strength, reconstructed image quality is high, and has the advantages such as less noise artifact, has greater advantage in clinical tumor radiotherapy, can improve examination efficiency, reduce the radiation injury of patient non-target organ.

The invention discloses a system for evaluating coronary artery stenosis through a photon CT low-dose low-concentration contrast agent scheme, and belongs to the field of medical images. The invention discloses a system for evaluating coronary artery stenosis by using a photon CT low-dose low-concentration contrast agent scheme. The system comprises a multi-energy spectrum data acquisition unit, a data preprocessing unit, an image generation unit, an image segmentation unit, a plaque analysis unit and a stenosis detection unit. The problems that in existing coronary artery CT examination, the radiation dosage is high, the contrast agent dosage is large, and the diagnosis process highly depends on physician experience, so that efficiency is low, and subjectivity is high are solved, the photon counting CT detector and optimized low-dosage scanning parameters are adopted, the deep learning algorithm and the multi-material decomposition technology are combined, and the CT examination efficiency is improved. High-quality coronary artery imaging and accurate stenosis evaluation under the conditions of low dosage and low concentration of contrast agents are realized, radiation exposure and contrast agent related risks of patients are remarkably reduced, and accuracy and reliability of coronary artery stenosis detection and plaque component analysis are improved.

The invention discloses a novel application of lobetyolin in improving or relieving phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake, and belongs to the technical field of biological medicines and functional foods. It is found that lobetyolin can effectively reduce the abnormally increased levels of phenylacetyl glutamine and phenylacetyl glycine in intestinal tract and peripheral blood of intestinal flora derived metabolites due to long-term low-dose ethanol intake, so that phenylacetyl metabolite unbalance is corrected; and further mechanism research shows that the regulating effect strictly depends on complete intestinal flora, so that the lobetyolin indirectly regulates and controls a downstream metabolic pathway by regulating the composition or function of intestinal microorganisms. On the basis, the invention provides application of lobetyolin in preparation of medicines, health foods or functional foods for improving or relieving phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake.